Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer

Nab-paclitaxel (NPT) combination with gemcitabine (Gem) represents the standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Genetic alterations of the RAS/RAF/MEK/ERK (MAPK) signaling pathway yielding constitutive activation of the ERK cascade have been implicated as drivers of PDAC. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Niranjan, Monahan, Sheena, Stefaniak, Alexis, Schwarz, Margaret A., Schwarz, Roderich E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797049/
https://www.ncbi.nlm.nih.gov/pubmed/29435178
http://dx.doi.org/10.18632/oncotarget.23684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797049/
https://www.ncbi.nlm.nih.gov/pubmed/29435178
http://dx.doi.org/10.18632/oncotarget.23684

Ejemplares similares